Vascular Therapeutics and its affiliate, Vascular Therapeutics Canada, have obtained worldwide exclusive rights to an unnamed antithrombotic drug from Recordati of Italy.
The patent-protected drug has already been through early preclinical development. However, using its screening assays, researchers at Vascular Therapeutics have identified novel properties and mechanisms of action of the drug, which it will explore.
Recordati will receive royalties on sales and has marketing rights in certain European countries. Further details were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze